medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2010, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2010; 27 (2)

Identificación de Cepas de Escherichia coli y klebsiella pneumoniae, Sospechosas de Producir β-lactamasas de Espectro Extendido en el Hospital Infantil del Estado de Sonora 2009

Cano-Rangel MA, Pérez-Moya G, Cervantes-Velázquez V, Durazo-Arvizu MÁ, Dorame-Castillo R, Cano-Corella MA

Language: Spanish
References: 15
Page: 108-112
PDF size: 115.55 Kb.


ABSTRACT

Objective: To establish a reference that allows us to detect bacteria capable of producing BLEE with resources readily available at most hospitals, including assays like Vitek-2; establishing susceptibility profile, following guidelines by CLSI (Clinical Laboratory Standards) which will be useful as a tool to adequately select an antimicrobial in infections caused by BLEE producing microorganisms
Material and Methods: a transversal ambispective study was made, which identified strains of E.coli and K. pneumonia obtained from Hospital Infantil del Estado de Sonora from January 1 to October 31st 2009 in children 0 to 18 years 11 months; antimicrobial susceptibility was obtained from the isolated strains by Vitek 2 system (bioMerix, Inc) with the AST GN-09 card. Once it was stablished, E.coli and K pneumonia strains suspicious for producing BLEE were identified as accorded by CLSI.
Results will be showed with descriptive statistics conveniently displayed as graphics.
Results: a total of 307 strains were isolated from both bacteria, 185 were E.coli and 122 K.pneumoniae. 30.2% from E.coli strains (30.2%) and 122 from K.pnuemoniae (44.2%) were suspicious for producing BLEE. On 33 cases of E.coli were associated with sepsis, 15 resulted in death; in 47 of K.. pneumoniae cases occurred the same
Conclusions: prevalence of enterobacteriacea producing BLEE have been shown to increase since their discovery, probably associated to selective pressure by cephalosporins among other antimicrobial; therefore making it imperative to know the local microbiology in order to offer an adequate antimicrobial treatment.


REFERENCES

  1. Hung LJ, Know BI, Hee LS. New definitions of Extended-Spectrum ß-lactamase Coferring Worldwide Emerging Antibiotic Resistance. Medicinal Research Reviews 2010 publicado on line http://www3.interscience.wiley.com/journal/109089146/issue

  2. Navarro NM, Moreno NB, López MB, Detección de Cepas de Escherichia coli y Klebsiella pneumoniae productoras de ß-lactamasas de Espectro extendido (BLEE) en el Hospital Infantil del Estado de Sonora. Bol Med Hosp Infant Mex 2005; 22: 64-70.

  3. Pujol M, Peña C. El Significado Clínico de las Betalactamasas de Espectro extendido. Enferm Infecc Microbiol 2003; 21: 69-71.

  4. Wen Z, Wei X, Xiao Y, Xue F, Hao F, Zhu Y, Ma N, Xiao Y, Wang H. Intervention study of the association of antibiotic utilization measures with control of extended-spectrum ß-lactamase (ESBL)-producing bacteria. Microb Infect 2010. doi:10.1016/j.micinf.2010.04.015 En prensa Available online 10 May 2010.

  5. Máttar S, Martínez Pedro. Emergencia de la Resistencia Antibiótica debida a llas ß-lactamasas de espectro extendido (BLEE): detección, Impacto Clínico y Epidemiología. Infectio 2007;11(1):25-35.

  6. Thomson K, Cornish NE, Hong SG, Hemrick K, Herdt.C, Moland E. Comparision of Phoenix and Vitek2 Extended-Spectrum ß-lactamase Detection Test for Analysis of Escherichia Coli and Klebsiella Isolates with Well- Caracterized ß- lactamases. J.Clin Microbiol2007;45:2380-4.

  7. Clinical Laboratory Standards Institute (CLSI). Antimicrobial susceptibility testing standards document M100- S18. Clinical Laboratory Standards Institute, Ed. Wayne, PA, 2008.

  8. Morales R. Terapia de bacterias productoras de â-lactamasas de Espectro Extendido. Rev Chil Infec 2003; 20(Supl1): S24-27.

  9. Crespo MP. La Lectura interpretativa del antibiograma: Una herramienta para predecir la resistencia bacteriana en el laboratorio de microbiología de rutina. Colomb Med 2002; 33:179-93.

  10. Sánchez M, Bello TH, Domínguez YM, Mella MS, Zimelman ZR, Gonzales R G. Transferencia de ß-lactamasas de espectro extendido desde cepas hospitalarias de Klebsiella pneumoniae a otras especies de enterobacteriacias. Rev Med Chile 2006; 134:415-20.

  11. Peterson LR. Antibiotic Policy and prescribing strategies for therapy of extended-spectrum ß-lactamase- producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008; 14(Sippl. 1): 181–4.

  12. Hernández JR, Pascual A, Cantón R,Martínez ML. Escherichia coli y Klebsiella penumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003;21 (2):77-82.

  13. Endimiani A, Peterson DL. Optimizing therapy for infections Caused by Enterobacteriaceae producing extendedspectrum ß-lactamses. Semin Respir Crit Care Med 2007; 28:646-55.

  14. Treviño M, Martinez LL, Romero JP, Varón C, Moldes L, García RC, Regueiro B. Comparación entre las pruebas para detección de betalactamasas de espectro extendido de los sistemas Vitek 2 y Phoenix. Enferm Infecc Microbiol Clin.2009.doi:10.1016/j.eimc.2009.02.005.

  15. Herada S, IshiiY, Yamaguchi K. Extended-spectrum ß-lactamses: Implications for de clinical laboratory and therapy. Korena J Lab Med 2008;28:401-12.




2020     |     www.medigraphic.com